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Monitoring of Mannan Antigenemia (Mn) and Antimannan
Antibodies (anti-Mn) for Screening of Invasive Candidiasis
in High Risk Hematooncological Patients
Zdenek Racil, Iva Kocmanova, Barbora Weinbergerova,
Martina Lengerova, Jana Winterova, Jiri Mayer. Dept. of Internal
Medicine Hemato-Oncology Masaryk University and University
Hospital Brno Jihlavska 20, 625 00 Brno, Czech Republic
Introduction and Methods: Between January 2005 and July 2007
we conducted a retrospective study to assess the diagnostic util-
ity of regular Mn and anti-Mn monitoring in neutropenic patients
with hematological malignancy at high risk for invasive fungal in-
fection, including invasive candidiasis (IC). Blood samples were ob-
tained twice weekly and Platelia Candida Ag and Platelia Candida
Ab/Ac/Ak test were used for Mn and anti-Mn detection. Classifi-
cation of IC cases was performed using EORTC/MSG criteria. All
patients received antifungal prophylaxis.
Results: Ninety-one high risk patients were screened for Mn and
anti-Mn during 104 treatment cycles. Detection of Mn and anti-Mn
was performed in 1199 (mean 11.5/patient) blood samples. Only
one patient fulfilled criteria for proven and probable IC (candi-
daemia caused by C. krusei) and thus incidence of IC was only
0.95% in our patient group. At least 1 sample with Mn > 0.25ng/ml
(intermediate) was detected in 35 (33.7%) and > 0.5ng/ml (posi-
tive) in 6 (5.8%) treatment cycles respectively. Only in 1 patient
Mn > 0.5ng/ml was detected in more than 1 sample - this was the
patient with serious typhlytis on voriconazole prophylaxis where
transient passage of Candida spp. or candida antigens could not
be excluded. Even more, simultaneously performed 1,3-ß-D glu-
can was also positive. All other Mn positive or intermediate re-
sults were not associated with proven/probable IC. The only pa-
tient with proven IC was Mn negative in repeat samples. Anti-
Mn was detected at least in 1 sample at intermediate range (>5
A.U./ml) in 56 (53.8%) treatment cycles and in 31 (29.8%) at pos-
itive range (>10 A.U./ml). Positive anti-Mn levels in repeat sam-
ples were found in 20 (19.2%) cycles. None of anti-Mn intermediate
or positive patients were classified as having proven/probable IC.
The only patient with candidaemia caused by C. krusei was anti-Mn
negative. There was no correlation between Mn/anti-Mn positivity
and empirical antifungal treatment or Candida spp. colonisation.
Conclusions: Contribution of Mn and anti-Mn detection in routing
screening of hemato-oncological patients in high risk of IFI is
limited. Our analysis showed that only when the Mn antigen is
detected (>0.5ng/ml) in repeat samples, IC should be considering.
On the other hand, the positivity (>10 A.U./ml) of anti-Mn was
very frequent (20–30% of treatment cycles) but never associated
with IC.
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Bacteremia in Children with Acute Lymphoblastic
Leukemia: A Five-year Experience in Pediatric
Hematology- Oncology Unit in Northern Greece
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Tragiannidis Athanasios1, Theodoridou Agelliki1,
Tsotoulidou Biki1, Tsapara Fani2, Raptis Georgios2,
Athanassiadou Fani1. 1Department of Pediatric Hematology and
Oncology, AHEPA Hospital, Thessaloniki, Greece; 2Department
of Microbiology, AHEPA Hospital, Thessaloniki, Greece
Background: Although the treatment of pediatric patients with
acute lymphoblastic leukemia (ALL) has dramatically improved, in-
fections still play a role in morbidity and mortality.
Objectives: The aim of this study is to determine the microbio-
logical spectrum and the antibiotic susceptibility during episodes
of fever-neutropenia (FEN) in children with ALL. Demographic data
of 46 patients with ALL admitted to the Department of Pediatric
Hematology and Oncology in AHEPA Hospital between January 2002
and December 2007 were evaluated retrospectively.
Methods: In 186 FEN episodes a total number of 42 infections were
microbiologically documented. FEN episode was defined as a single
temperature of the axilla above 38.3°C or a temperature of 38.0°C
or higher measured on at least two occasions with 4-h intervals
without using antipyretic drugs and when the absolute neutrophil
count was lower than <500/L or less than 1000/L with a predictive
decrease to <500/L. Peripheral blood smear, urine and blood cul-
tures obtained via peripheral venous puncture or through a central
venous catheter were evaluated.
Results: During the 5-year study period, a total of 186 FEN episodes
occurred in children with ALL, with male/female ratio 27/19 (me-
dian age 5 years, ranging from 0.5 to 9 yrs). Of all organisms iso-
lated 54.7% were Gram-positive and 45.2% were Gram-negative.
The predominant Gram-positive microbes were coagulase nega-
tive staphylococci. Their susceptibility was found excellent to gly-
copeptides but moderate to clindamycin and aminoglycocides. The
predominant Gram-negative bacteria were Escherichia coli 52.6%.
Conclusions: These results are comparable to the international
data, suggesting the increasing risk of Gram-positive infections.
On the other hand, the incidence of Gram-negative infections is
increasing, as well. Isolation of multiresistant strains is a problem
faced in these children. These data may help in the future to adopt
a more selective management strategy for children with ALL.
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Evaluation of Diagnostic Tools for Invasive Aspergillosis in
Children with Cancer
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Introduction: Fungal infections are one of the most serious com-
plications of anti-cancer treatment. The highest mortality rate
is blamed on invasive aspergillosis (IA). Clinical symptoms of As-
pergillus infection are usually unspecific and its diagnostic proce-
dure still causes large problems. The aim of the study was an anal-
ysis of the IA in terms of clinical symptoms, required diagnostic
tools and the application of treatment and prognosis.
Materials: The retrospective analysis of clinical records from our
Oncoahematology Unit between 2005-2007 revealed that among 28
pediatric neutropenic patients with symptoms of sepsis five chil-
dren had IA The records of these patients were analyzed to define
the most useful method which gave the most reliable diagnosis
of IA. Among diagnostic methods computer tomography (CTG) or
magnetic resonance where considered, as well as galactomannan
antigen and fungal DNA by PCR method were assessed on serial
blood samples.
Results: The most common clinical form of IA was pulmonary as-
pergillosis (3 of 5 cases), one had CNS involvement and one liver
localization. Three patients needed to be treated in ICU, and two
of them died. Treatment regimen consists of 2 antifungal drugs:
voriconazol with amphotericin B or voriconazol with caspofungin.
Based on symptoms-to-treatment time in our cases the most re-
liable method was computed tomography or magnetic resonance
imaging. Fungal DNA had only supportive role in diagnosis (2 of 5
were positive) and galactomannan antigen assessment had less use-
ful test for diagnosis of IA because of many false positive results.
However, serial measurement of galactomannan antigen seems to
be a very good marker of the treatment efficacy.
Conclusions: The application of all diagnostic tools is needed for
proper assessment of invasive aspegillosis. Some of these methods
may additionally serve for evaluation of treatment strategies.
